Találati lista | Tudóstér

001-es BibID:	BIBFORM069431
Első szerző:	Farmakis, Dimitrios
Cím:	Levosimendan beyond inotropy and acute heart failure : evidence of pleiotropic effects on the heart and other organs : an expert panel position paper / Farmakis Dimitrios, Alvarez Julian, Gal Tuvia Ben, Brito Dulce, Fedele Francesco, Fonseca Candida, Gordon Anthony C., Gotsman Israel, Grossini Elena, Guarracino Fabio, Harjola Veli-Pekka, Hellman Yaron, Heunks Leo, Ivancan Visnja, Karavidas Apostolos, Kivikko Matti, Lomivorotov Vladimir, Longrois Dan, Masip Josep, Metra Marco, Morelli Andrea, Nikolaou Maria, Papp Zoltán, Parkhomenko Alexander, Poelzl Gerhard, Pollesello Piero, Ravn Hanne Berg, Rex Steffen, Riha Hynek, Ricksten Sven-Erik, Schwinger Robert H. G., Vrtovec Bojan, Yilmaz M. Birhan, Zielinska Marzenna, Parissis John
Dátum:	2016
ISSN:	0167-5273
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	International Journal Of Cardiology 222 (2016), p. 303-312. -
További szerzők:	Alvarez, Julian Gal, Tuvia Ben Brito, Dulce Fedele, Francesco Fonseca, Candida Gordon, Anthony C. Gotsman, Israel Grossini, Elena Guarracino, Fabio Harjola, Veli-Pekka Hellman, Yaron Heunks, Leo Ivancan, Visnja Karavidas, Apostolos Kivikko, Matti Lomivorotov, Vladimir Longrois, Dan Masip, Josep Metra, Marco Morelli, Andrea Nikolaou, Maria Papp Zoltán (1965-) (kardiológus, élettanász) Parkhomenko, Alexander Poelzl, Gerhard Pollesello, Piero Ravn, Hanne Berg Rex, Steffen Riha, Hynek Ricksten, Sven-Erik Schwinger, Robert H. G. Vrtovec, Bojan Yilmaz, Mehmet Birhan Zielinska, Marzenna Parissis, John
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM070104
035-os BibID:	(Wos)000405571400002 (Scopus)85020004824
Első szerző:	Harjola, Veli-Pekka
Cím:	Organ dysfunction, injury and failure in acute heart failure : from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) / Harjola Veli-Pekka, Mullens Wilfried, Banaszewski Marek, Bauersachs Johann, Brunner-La Rocca Hans-Peter, Chioncel Ovidiu, Collins Sean P., Doehner Wolfram, Filippatos Gerasimos S., Flammer Andreas J., Fuhrmann Valentin, Lainscak Mitja, Lassus Johan, Legrand Matthieu, Masip Josep, Mueller Christian, Papp Zoltán, Parissis John, Platz Elke, Rudiger Alain, Ruschitzka Frank, Schäfer Andreas, Seferovic Petar M., Skouri Hadi, Yilmaz Mehmet Birhan, Mebazaa Alexandre
Dátum:	2017
ISSN:	1388-9842
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	European Journal Of Heart Failure. - 19 : 7 (2017), p. 821-836. -
További szerzők:	Mullens, Wilfried Banaszewski, Marek Bauersachs, Johann Brunner-La Rocca, Hans-Peter Chioncel, Ovidiu Collins, Sean P. Doehner, Wolfram Filippatos, Gerasimos S. Flammer, Andreas J. Fuhrmann, Valentin Lainscak, Mitja Lassus, Johan Legrand, Matthieu Masip, Josep Mueller, Christian Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Platz, Elke Rudiger, Alain Ruschitzka, Frank Schäfer, Andreas Seferović, Petar M. Skouri, Hadi Yilmaz, Mehmet Birhan Mebazaa, Alexandre
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM076736
035-os BibID:	(WoS)000501730100012 (Scopus)85075326564
Első szerző:	Maack, Christoph
Cím:	Treatments targeting inotropy : a position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology / Christoph Maack, Thomas Eschenhagen, Nazha Hamdani, Frank R. Heinzel, Alexander R. Lyon, Dietmar J. Manstein, Joseph Metzger, Zoltán Papp, Carlo G. Tocchetti, M. Birhan Yilmaz, Stefan D. Anker, Jean-Luc Balligand, Johann Bauersachs, Dirk Brutsaert, Lucie Carrier, Stefan Chlopicki, John G. Cleland, Rudolf A. de Boer, Alexander Dietl, Rodolphe Fischmeister, Veli-Pekka Harjola, Stephane Heymans, Denise Hilfiker-Kleiner, Johannes Holzmeister, Gilles de Keulenaer, Giuseppe Limongelli, Wolfgang A. Linke, Lars H. Lund, Josep Masip, Marco Metra, Christian Mueller, Burkert Pieske, Piotr Ponikowski, Arsen Ristic, Frank Ruschitzka, Petar M. Seferovic, Hadi Skouri, Wolfram H. Zimmermann, Alexandre Mebazaa
Dátum:	2019
ISSN:	0195-668X
Megjegyzések:	Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2+. Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation-contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.
Tárgyszavak:	idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Heart failure Acute decompensated heart failure Inotropes Cardiogenic shock Excitation-contraction coupling Calcium Sarcomeres Mitochondria Energetics Adrenergic receptors Contractility Levosimendan Omecamtiv mecarbil Nitroxyl
Megjelenés:	European Heart Journal. - 40 : 44 (2019), p. 3626-3640. -
További szerzők:	Eschenhagen, Thomas Hamdani, Nazha Heinzel, Frank R. Lyon, Alexander Manstein, Dietmar J. Metzger József Papp Zoltán (1965-) (kardiológus, élettanász) Tocchetti, Carlo Gabriele Yilmaz, Mehmet Birhan Anker, Stefan D. Balligand, Jean-Luc Bauersachs, Johann Brutsaert, Dirk L. Carrier, Lucie Chlopicki, Stefan Cleland, John G. Boer, Rudolf A. de Dietl, Alexander Fischmeister, Rodolphe Harjola, Veli-Pekka Heymans, Stephane Hilfiker-Kleiner, Denise Holzmeister, Johannes De Keulenaer, Gilles Limongelli, Giuseppe Linke, Wolfgang A. Lund, Lars H. Masip, Josep Metra, Marco Mueller, Christian Pieske, Burkert Ponikowski, Piotr Ristić, Arsen D. Ruschitzka, Frank Seferović, Petar M. Skouri, Hadi Zimmermann, Wolfram H. Mebazaa, Alexandre
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:

BIBFORM090883

Első szerző:

Papp Zoltán (kardiológus, élettanász)

Cím:

Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero

Dátum:

2020

ISSN:

0160-2446

Megjegyzések:

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use

Tárgyszavak:

Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk

Megjelenés:

Journal Of Cardiovascular Pharmacology. - 76 : 1 (2020), p. 4-22. -

További szerzők:

Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero

Internet cím:

Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat

Lásd még:

Egyéb kapcsolat (1)

Borító:

Saját polcon:

001-es BibID:

BIBFORM090869

035-os BibID:

(cikkazonosító)e19

Első szerző:

Papp Zoltán (kardiológus, élettanász)

Cím:

Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero

Dátum:

2020

Megjelenés:

Utánközlés / Másodközlés

ISSN:

2057-7540 2057-7559

Megjegyzések:

Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use

Tárgyszavak:

Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk

Megjelenés:

Cardiac Failure Review. - 6 (2020), p. 1-16. -

További szerzők:

Internet cím:

Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat

Lásd még:

Utánközlés (1)

Borító:

Saját polcon:

001-es BibID:	BIBFORM114410
035-os BibID:	(scopus)85169671684
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period : The multinational randomized trial / Pölzl Gerhard, Altenberger Johann, Comín-Colet Josep, Delgado Juan F., Fedele Francesco, Garcia-González Martín Jesús, Gustafsson Finn, Masip Josep, Papp Zoltán, Störk Stefan, Ulmer Hanno, Maier Sarah, Vrtovec Bojan, Wikström Gerhard, Zima Endre, Bauer Axel, LeoDOR Investigators
Dátum:	2023
ISSN:	1388-9842 1879-0844
Megjegyzések:	Aim: The LeoDOR trial explored the efficacy and safety of intermittent levosimendan therapy in the vulnerable phase following a hospitalization for acute heart failure (HF). Methods and results: In this prospective multicentre, double-blind, two-armed trial, patients with advanced HF were randomized 2:1 at the end of an index hospitalization for acute HF to intermittent levosimendan therapy or matching placebo for 12 weeks. All patients had left ventricular ejection fraction (LVEF) ?30% during index hospitalization. Levosimendan was administered according to centre preference either as 6 h infusion at a rate of 0.2 ?g/kg/min every 2 weeks, or as 24 h infusion at a rate of 0.1 ?g/kg/min every 3 weeks. The primary efficacy assessment after 14 weeks was based on a global rank score consisting of three hierarchical groups. Secondary clinical endpoints included the composite risk of tiers 1 and 2 at 14 and 26 weeks, respectively. Due to the COVID-19 pandemic, the planned number of patients could not be recruited. The final modified intention-to-treat analysis included 145 patients (93 in the combined levosimendan arm, 52 in the placebo arm), which reduced the statistical power to detect a 20% risk reduction in the primary endpoint to 60%. Compared with placebo, intermittent levosimendan had no significant effect on the primary endpoint: the mean rank score was 72.55 for the levosimendan group versus 73.81 for the placebo group (p = 0.863). However, there was a signal towards a higher incidence of the individual clinical components of the primary endpoint in the levosimendan group versus the placebo group both after 14 weeks (hazard ratio [HR] 2.94, 95% confidence interval [CI] 1.12-7.68; p = 0.021) and 26 weeks (HR 1.64, 95% CI 0.87-3.11; p = 0.122). Conclusions: Among patients recently hospitalized with HF and reduced LVEF, intermittent levosimendan therapy did not improve post-hospitalization clinical stability.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	European Journal Of Heart Failure. - 25 : 11 (2023), p. 2007-2017. -
További szerzők:	Altenberger, Johann Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Garcia-González, Martín J. Gustafsson, Finn Masip, Josep Papp Zoltán (1965-) (kardiológus, élettanász) Störk, Stefan Ulmer, Hanno Maier, Sarah Vrtovec, Bojan Wikström, Gerhard Zima Endre (1974-) (kardiológus) Bauer, Axel LeoDOR Investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM090865
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period / Pölzl Gerhard, Allipour Birgani Shadab, Comín-Colet Josep, Delgado Juan F., Fedele Francesco, Garcia-Gonzáles Martín J., Gustafsson Finn, Masip Josep, Papp Zoltán, Störk Stefan, Ulmer Hanno, Vrtovec Bojan, Wikström Gerhard, Altenberger Johann
Dátum:	2019
ISSN:	2055-5822
Megjegyzések:	Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in recent times. Levosimendan is a first-in-class calcium sensitizer and potassium channel opener indicated for the management of acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were designed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR (levosimendan infusions for patients with advanced chronic heart failure), a randomized, double-blind, placebo-controlled, international, multicentre trial that will explore the efficacy and safety of intermittent levosimendan therapy, in addition to optimized standard therapy, in patients following hospitalization for acute HF. Salient features of LeoDOR include the use of two treatment regimens, in order to evaluate the effects of different schedules and doses of levosimendan during a 12 week treatment phase, and the use of a global rank primary endpoint, in which all patients are ranked across three hierarchical groups ranging from time to death or urgent heart transplantation or implantation of a ventricular assist device to time to rehospitalization and, lastly, time-averaged proportional change in N-terminal pro-brain natriuretic peptide. Secondary endpoints include changes in HF symptoms and functional status at 14 weeks.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	ESC heart failure. - 6 : 1 (2019), p. 174-181. -
További szerzők:	Allipour Birgani, Shadab Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Garcia-González, Martín J. Gustafsson, Finn Masip, Josep Papp Zoltán (1965-) (kardiológus, élettanász) Störk, Stefan Ulmer, Hanno Vrtovec, Bojan Wikström, Gerhard Altenberger, Johann
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM070106
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive use of levosimendan in advanced heart failure : need for stronger evidence in a field in dire need of a useful therapy / Pölzl Gerhard, Altenberger Johann, Baholli Loant, Beltrán Paola, Borbély Attila, Comin-Colet Josep, Delgado Juan F., Fedele Francesco, Fontana Antonella, Fruhwald Friedrich, Giamouzis Gregory, Giannakoulas George, Garcia-González Martín J., Gustafsson Finn, Kaikkonen Kari, Kivikko Matti, Kubica Jacek, von Lewinski Dirk, Löfman Ida, Malfatto Gabriella, Manito Nicolás, Martínez-Sellés Martin, Masip Josep, Merkely Bela, Morandi Fabrizio, Mølgaard Henning, Oliva Fabrizio, Pantev Emil, Papp Zoltán, Perna Gian Piero, Pfister Roman, Piazza Vito, Bover Ramón, Rangel-Sousa Diego, Recio-Mayoral Alejandro, Reinecke Alexander, Rieth Andreas, Sarapohja Toni, Schmidt Gunter, Seidel Mirko, Störk Stefan, Vrtovec Bojan, Wikström Gerhard, Yerly Patrik, Pollesello Piero
Dátum:	2017
ISSN:	0167-5273
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	International Journal Of Cardiology. - 243 (2017), p. 389-395. -
További szerzők:	Altenberger, Johann Baholli, Loant Beltrán, Paola Borbély Attila (1978-) (kardiológus) Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Fontana, Antonella Fruhwald, Friedrich Giamouzis, Gregory Giannakoulas, George Garcia-González, Martín J. Gustafsson, Finn Kaikkonen, Kari Kivikko, Matti Kubica, Jacek von Lewinski, Dirk Löfman, Ida Malfatto, Gabriella Manito, Nicolás Martínez-Sellés, Martin Masip, Josep Merkely Béla (1965-) (orvos) Morandi, Fabrizio Mølgaard, Henning Oliva, Fabrizio Pantev, Emil Papp Zoltán (1965-) (kardiológus, élettanász) Perna, Gian Piero Pfister, Roman Piazza, Vito Bover, Ramón Rangel-Sousa, Diego Recio-Mayoral, Alejandro Reinecke, Alexander Rieth, Andreas Sarapohja, Toni Schmidt, Gunter Seidel, Mirko Störk, Stefan Vrtovec, Bojan Wikström, Gerhard Yerly, Patrik Pollesello, Piero
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: